Current trends in clinical trials and the development of small molecule epigenetic inhibitors as cancer therapeutics

References

• Singh M, Kumar V, Sehrawat N et al. Current paradigms in epigenetic anticancer therapeutics and future challenges. Semin. Cancer Biol. 83, 422–440 (2022).
   PubMed Web of Science ®Google Scholar
• Su M, Zhang Z, Zhou L, Han C, Huang C, Nice EC. Proteomics, personalized medicine and cancer. Cancers (Basel) 13(11), 2512 (2021).
   PubMed Web of Science ®Google Scholar
• Kim D-S, Camacho CV, Kraus WL. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance. Exp. Mol. Med. 53(1), 42–51 (2021).
   PubMed Web of Science ®Google Scholar
• Coyle KM, Boudreau JE, Marcato P. Genetic mutations and epigenetic modifications: driving cancer and informing precision medicine. Biomed. Res. Int. 2017, 1–18 (2017).
   Web of Science ®Google Scholar
• Xiao W, Zhou Q, Wen X et al. Small-molecule inhibitors overcome epigenetic reprogramming for cancer therapy. Front. Pharmacol. 12, 702360 (2021).
   PubMed Web of Science ®Google Scholar
• Xu X, Peng Q, Jiang X et al. Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential. Exp. Mol. Med. 55(7), 1357–1370 (2023).
   PubMed Web of Science ®Google Scholar
• Nepali K, Liou J-P. Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends. J. Biomed. Sci. 28(1), 27 (2021).
   PubMed Web of Science ®Google Scholar
• Brown JAL, Bourke E, Eriksson LA, Kerin MJ. Targeting cancer using KAT inhibitors to mimic lethal knockouts. Biochem. Soc. Trans. 44(4), 979–986 (2016).
   PubMedGoogle Scholar
• Feehley T, O'Donnell CW, Mendlein J, Karande M, McCauley T. Drugging the epigenome in the age of precision medicine. Clin. Epigenetics 15(1), 6 (2023).
   PubMed Web of Science ®Google Scholar
• Bennett RL, Licht JD. Targeting epigenetics in cancer. Annu. Rev. Pharmacol. Toxicol. 58(1), 187–207 (2018).
   PubMedGoogle Scholar
• Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 150(1), 12–27 (2012).
   PubMed Web of Science ®Google Scholar
• Singh M, Kumar V, Sehrawat N et al. Current paradigms in epigenetic anticancer therapeutics and future challenges. Semin. Cancer Biol. 83, 422–440 (2022).
   PubMed Web of Science ®Google Scholar
• Cossío FP, Esteller M, Berdasco M. Towards a more precise therapy in cancer: exploring epigenetic complexity. Curr. Opin. Chem. Biol. 2020, 41–49 (2020).
   Google Scholar
• Biswas S, Rao CM. Epigenetics in cancer: fundamentals and beyond. Pharmacol. Ther. 173, 118–134 (2017).
   PubMed Web of Science ®Google Scholar
• Rodríguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat. Med. 17(3), 330–339 (2011).
   PubMed Web of Science ®Google Scholar
• Ren L, Yang Y, Li W et al. Recent advances in epigenetic anticancer therapeutics and future perspectives. Front. Genet. 13, 1085391 (2023).
   PubMed Web of Science ®Google Scholar
• Copeland RA, Olhava EJ, Scott MP. Targeting epigenetic enzymes for drug discovery. Curr. Opin. Chem. Biol. 14(4), 505–510 (2010).
   PubMed Web of Science ®Google Scholar
• Liu R, Wu J, Guo H et al. Post-translational modifications of histones: mechanisms, biological functions, and therapeutic targets. MedComm. (Beijing) 4(3), e292 (2023).
   PubMedGoogle Scholar
• Idrissou M, Judes G, Daures M et al. TIP60 inhibitor TH1834 reduces breast cancer progression in xenografts in mice. OMICS 23(9), 457–459 (2019).
   PubMed Web of Science ®Google Scholar
• Gajer JM, Furdas SD, Gründer A et al. Histone acetyltransferase inhibitors block neuroblastoma cell growth in vivo. Oncogenesis 4(2), e137 (2015).
   PubMedGoogle Scholar
• Prakash A, Garcia-Moreno J, Brown J, Bourke E. Clinically applicable inhibitors impacting genome stability. Molecules 23(5), 1166 (2018).
   PubMed Web of Science ®Google Scholar
• Wang Y, Xie Q, Tan H et al. Targeting cancer epigenetic pathways with small-molecule compounds: therapeutic efficacy and combination therapies. Pharmacol. Res. 173, 105702 (2021).
   PubMed Web of Science ®Google Scholar
• Huang M, Huang J, Zheng Y, Sun Q. Histone acetyltransferase inhibitors: an overview in synthesis, structure-activity relationship and molecular mechanism. Eur. J. Med. Chem. 178, 259–286 (2019).
   PubMed Web of Science ®Google Scholar
• Whedon SD, Cole PA. KATs off: biomedical insights from lysine acetyltransferase inhibitors. Curr. Opin. Chem. Biol. 72, 102255 (2023).
   PubMed Web of Science ®Google Scholar
• Wu D, Qiu Y, Jiao Y, Qiu Z, Liu D. Small molecules targeting HATs, HDACs, and BRDs in cancer therapy. Front. Oncol. 10, 560487 (2020).
   PubMedGoogle Scholar
• McGuire A, Casey MC, Shalaby A et al. Quantifying Tip60 (Kat5) stratifies breast cancer. Sci. Rep. 9(1), 3819 (2019).
   PubMedGoogle Scholar
• Gao C, Bourke E, Scobie M et al. Rational design and validation of a Tip60 histone acetyltransferase inhibitor. Sci. Rep. 4(1), 5372 (2014).
   PubMedGoogle Scholar
• Brown JAL. Patent spotlight: small-molecule lysine acetyltransferase inhibitors (KATi). Pharm. Pat. Anal. 9(1), 17–28 (2020).
   PubMed Web of Science ®Google Scholar
• Sommerhalder D, Hamilton EP, Mukohara T et al. First-in-human Phase I dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors. J. Clin. Oncol. 41(Suppl. 16), 1054–1054 (2023).
   Web of Science ®Google Scholar
• Maldonato BJ, Vergara AG, Yadav J et al. Epigenetics in drug disposition & drug therapy: symposium report of the 24th North American meeting of the International Society for the Study of Xenobiotics (ISSX). Drug Metab. Rev. 54(3), 318–330 (2022).
   PubMed Web of Science ®Google Scholar
• Bhatnagar A, Krick K, Karisetty BC, Armour EM, Heller EA, Elefant F. Tip60's novel RNA-binding function modulates alternative splicing of pre-mRNA targets implicated in Alzheimer's disease. J. Neurosci. 43(13), 2398–2423 (2023).
   PubMed Web of Science ®Google Scholar
• Shi Y, Zhang H, Huang S et al. Epigenetic regulation in cardiovascular disease: mechanisms and advances in clinical trials. Signal. Transduct. Target Ther. 7(1), 200 (2022).
   PubMed Web of Science ®Google Scholar
• Cheng Y, He C, Wang M et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct. Target Ther. 4(1), 62 (2019).
   PubMedGoogle Scholar
• Srivastava S, Kumar S, Bhatt R, Ramachandran R, Trivedi AK, Kundu TK. Lysine acetyltransferases (KATs) in disguise: diseases implications. J. Biochem. 173(6), 417–433 (2023).
   PubMed Web of Science ®Google Scholar
• Fueyo-González F, Vilanova G, Ningoo M et al. Small-molecule TIP60 inhibitors enhance regulatory T cell induction through TIP60-P300 acetylation crosstalk. iScience 26(12), 108491 (2023).
   PubMed Web of Science ®Google Scholar
• Török N, Tanaka M, Vécsei L. Searching for peripheral biomarkers in neurodegenerative diseases: the tryptophan-kynurenine metabolic pathway. Int. J. Mol. Sci. 21(24), 9338 (2020).
   PubMed Web of Science ®Google Scholar
• Davalos V, Esteller M. Cancer epigenetics in clinical practice. CA Cancer J. Clin. 73(4), 376–424 (2023).
   PubMed Web of Science ®Google Scholar
• Feng S, De Carvalho DD. Clinical advances in targeting epigenetics for cancer therapy. FEBS J. 289(5), 1214–1239 (2022).
   PubMed Web of Science ®Google Scholar
• Gomez S, Tabernacki T, Kobyra J, Roberts P, Chiappinelli KB. Combining epigenetic and immune therapy to overcome cancer resistance. Semin. Cancer Biol. 65, 99–113 (2020).
   PubMed Web of Science ®Google Scholar
• Morel D, Jeffery D, Aspeslagh S, Almouzni G, Postel-Vinay S. Combining epigenetic drugs with other therapies for solid tumors – past lessons and future promise. Nat. Rev. Clin. Oncol. 17(2), 91–107 (2020).
   PubMed Web of Science ®Google Scholar
• Majchrzak-Celińska A, Warych A, Szoszkiewicz M. Novel approaches to epigenetic therapies: from drug combinations to epigenetic editing. Genes (Basel) 12(2), 208 (2021).
   PubMed Web of Science ®Google Scholar
• Martinez-Useros J, Martin-Galan M, Florez-Cespedes M, Garcia-Foncillas J. Epigenetics of most aggressive solid tumors: pathways, targets and treatments. Cancers (Basel) 13(13), 3209 (2021).
   PubMed Web of Science ®Google Scholar
• Nervi C, De Marinis E, Codacci-Pisanelli G. Epigenetic treatment of solid tumors: a review of clinical trials. Clin. Epigenetics 7(1), 127 (2015).
   PubMedGoogle Scholar
• Jin N, George TL, Otterson GA et al. Advances in epigenetic therapeutics with focus on solid tumors. Clin. Epigenetics 13(1), 83 (2021).
   PubMed Web of Science ®Google Scholar
• Liu Z, Gao Y, Li X. Cancer epigenetics and the potential of epigenetic drugs for treating solid tumors. Expert Rev. Anticancer Ther. 19(2), 139–149 (2019).
   PubMed Web of Science ®Google Scholar
• Statista. https://www.statista.com/statistics/1306445/global-epigenetics-market-size/ (2021).
   Google Scholar
• Amin Omar M. Market analysis of epigenetics. In: 6th World Congress on Epigenetics and Chromosome. J. Clin. Epigenetics 5(1), (2019).
   Google Scholar
• iHealthcareAnalyst, Inc. Epigenetics drugs Market forecast. https://www.ihealthcareanalyst.com/epigenetics-drugs-market-forecast-demand-cancer-heart-diseases-diabetes-mental-illnesses-treatment/ (2023).
   Google Scholar
• iHealthcareAnalyst, Inc. Epigenetics drugs market and forecast 2023–2029. https://www.ihealthcareanalyst.com/epigenetics-drugs-market-forecast-demand-cancer-heart-diseases-diabetes-mental-illnesses-treatment/ (2023).
   Google Scholar
• García-Giménez JL, Seco-Cervera M, Tollefsbol TO et al. Epigenetic biomarkers: current strategies and future challenges for their use in the clinical laboratory. Crit. Rev. Clin. Lab. Sci. 54(7–8), 529–550 (2017).
   PubMed Web of Science ®Google Scholar
• Singh D, Khan MA, Siddique HR. Role of epigenetic drugs in sensitizing cancers to anticancer therapies: emerging trends and clinical advancements. Epigenomics 15(8), 517–537 (2023).
   PubMed Web of Science ®Google Scholar
• Babar Q, Saeed A, Tabish TA, Pricl S, Townley H, Thorat N. Novel epigenetic therapeutic strategies and targets in cancer. Biochim. et Biophys. Acta (BBA) – Molecular Basis of Disease 1868(12), 166552 (2022).
   PubMed Web of Science ®Google Scholar